Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     

  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     

  • Bitcoin GBP

    50,307.52
    +3,062.98 (+6.48%)
     

  • CMC Crypto 200

    1,361.16
    +84.18 (+6.59%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     
MONEY:

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

Four-strain AstraZeneca flu vaccine wins EU green light

Reuters - UK Focus

LONDON, Sept 20 (Reuters) - A new four-in-one flu vaccine from AstraZeneca (NYSE: AZN - news) has been recommended for approval in Europe, boosting commercial prospects for the next-generation product.

Following Friday's green light from the European Medicines Agency, AstraZeneca said it aimed to replace its current three-strain Fluenz vaccine with quadrivalent Fluenz Tetra from the 2014/15 flu season - assuming the agency's opinion is endorsed by the European Commission.

Unlike traditional injections, AstraZeneca's vaccine is sprayed into the nose. It has been recommended in Europe for preventing seasonal influenza in children.

Quadrivalent flu vaccines - which also include injectable versions from Sanofi (NasdaqGM: GCVRZ - news) and GlaxoSmithKline (LSE: GSK.L - news) - are expected to boost vaccine manufacturers' revenues in the coming years.